Lytix Biopharma ASA (OSL:LYTIX)
Norway · Delayed Price · Currency is NOK | Market Cap | 645.96M +19.5% |
| Revenue (ttm) | n/a |
| Net Income | -94.62M |
| EPS | -1.34 |
| Shares Out | 76.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,574 |
| Open | 8.76 |
| Previous Close | 8.40 |
| Day's Range | 8.00 - 8.76 |
| 52-Week Range | 6.68 - 11.90 |
| Beta | -0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About Lytix Biopharma ASA
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as he... [Read more]
Financial Performance
Financial StatementsNews
Lytix Biopharma ASA Earnings Call Transcript: Q2 2026
FDA cleared the path for a registrational phase III trial in melanoma, enabling a defined regulatory route and supporting active partnership discussions. Strong interim efficacy data and a solid cash position underpin continued progress, though additional funding will be required.
Lytix Biopharma ASA Quarterly report: Q2 2026
Lytix Biopharma ASA has published its Q2 2026 quarterly earnings report on August 27, 2026.
Lytix Biopharma ASA Slides: Q2 2026
Lytix Biopharma ASA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 27, 2026.
Lytix Biopharma ASA Earnings Call Transcript: Q1 2026
Ruxotemitide showed strong phase II results in melanoma and basal cell carcinoma, with durable responses and systemic immune activation. Financially, Q1 2026 saw increased R&D spending and a strengthened cash position, supporting ongoing clinical development and upcoming registrational studies.
Lytix Biopharma ASA Slides: Q1 2026
Lytix Biopharma ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 21, 2026.
Lytix Biopharma ASA Quarterly report: Q1 2026
Lytix Biopharma ASA has published its Q1 2026 quarterly earnings report on May 21, 2026.
Lytix Biopharma ASA Earnings Call Transcript: Q4 2025
Strong clinical data and reduced costs position the company for pivotal studies and commercialization, with NOK 77 million raised to extend runway into 2027. Promising interim results and strategic partnerships are expected to drive value in 2026.
Lytix Biopharma ASA Annual report: Q4 2025
Lytix Biopharma ASA has published its Q4 2025 annual report on February 12, 2026.
Lytix Biopharma ASA Quarterly report: Q4 2025
Lytix Biopharma ASA has published its Q4 2025 quarterly earnings report on February 12, 2026.
Lytix Biopharma ASA Slides: Q4 2025
Lytix Biopharma ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Lytix Biopharma ASA Earnings Call Transcript: Q3 2025
Strong clinical data for ruxotemitide in BCC and melanoma support advancement toward commercialization, with stable financials and sufficient funding through 2026. Phase III studies are planned, with partnerships considered for financing.
Lytix Biopharma ASA Earnings release: Q3 2025
Lytix Biopharma ASA released its Q3 2025 earnings on November 18, 2025, summarizing the period's financial results.
Lytix Biopharma ASA Slides: Q3 2025
Lytix Biopharma ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 18, 2025.